KYTX
Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.25
−1.20%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
Market Cap
$510.21M
MomentumView details →
1D Return
−1.20%
YTD Return
−12.29%
RSI (14)
49.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
Market Cap
$510.21M
RSI (14)
49.3
MomentumView details →
1D Return
−1.20%
YTD Return
−12.29%
SummaryUpdated Jun 1, 2026
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Emeryville, California. Originally incorporated as BAIT Therapeutics, Inc., the company changed its name to Kyverna Therapeutics in October 2019. Kyverna went public in February 2024 and focuses on developing innovative cell therapies specifically designed to treat autoimmune diseases, representing a novel approach in a field traditionally dominated by immunosuppressive drugs and biologics.
Similar companies
Latest newsMore news →
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kyverna Therapeutics' miv-cel for the treatment of non-active secondary progressive multiple sclerosis (naSPMS).24d agoKyverna Therapeutics and ElevateBio entered into a commercial manufacturing and supply agreement for Miv-cel.40d agoKyverna Therapeutics signed a Clinical and Commercial Supply Agreement with ElevateBio Basecamp for development and manufacturing services for its lead product candidate mivocabtagene autoleucel (miv-cel).40d ago